Global Solid Tumor Non-Conventional Testing Market Research Report 2025

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Solid Tumor Non-Conventional Testing Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Fluorescence in-situ Hybridization (FISH)
1.2.3 Immunohistochemistry (IHC)
1.2.4 Polymerase Chain Reaction (PCR)
1.2.5 Next-generation Sequencing (NGS)
1.2.6 Others
1.3 Market by Application
1.3.1 Global Solid Tumor Non-Conventional Testing Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospitals
1.3.3 Pharmaceutical and Biotechnology Companies
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Solid Tumor Non-Conventional Testing Market Perspective (2020-2031)
2.2 Global Solid Tumor Non-Conventional Testing Growth Trends by Region
2.2.1 Global Solid Tumor Non-Conventional Testing Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Solid Tumor Non-Conventional Testing Historic Market Size by Region (2020-2025)
2.2.3 Solid Tumor Non-Conventional Testing Forecasted Market Size by Region (2026-2031)
2.3 Solid Tumor Non-Conventional Testing Market Dynamics
2.3.1 Solid Tumor Non-Conventional Testing Industry Trends
2.3.2 Solid Tumor Non-Conventional Testing Market Drivers
2.3.3 Solid Tumor Non-Conventional Testing Market Challenges
2.3.4 Solid Tumor Non-Conventional Testing Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Solid Tumor Non-Conventional Testing Players by Revenue
3.1.1 Global Top Solid Tumor Non-Conventional Testing Players by Revenue (2020-2025)
3.1.2 Global Solid Tumor Non-Conventional Testing Revenue Market Share by Players (2020-2025)
3.2 Global Solid Tumor Non-Conventional Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Solid Tumor Non-Conventional Testing Revenue
3.4 Global Solid Tumor Non-Conventional Testing Market Concentration Ratio
3.4.1 Global Solid Tumor Non-Conventional Testing Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Solid Tumor Non-Conventional Testing Revenue in 2024
3.5 Global Key Players of Solid Tumor Non-Conventional Testing Head office and Area Served
3.6 Global Key Players of Solid Tumor Non-Conventional Testing, Product and Application
3.7 Global Key Players of Solid Tumor Non-Conventional Testing, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Solid Tumor Non-Conventional Testing Breakdown Data by Type
4.1 Global Solid Tumor Non-Conventional Testing Historic Market Size by Type (2020-2025)
4.2 Global Solid Tumor Non-Conventional Testing Forecasted Market Size by Type (2026-2031)
5 Solid Tumor Non-Conventional Testing Breakdown Data by Application
5.1 Global Solid Tumor Non-Conventional Testing Historic Market Size by Application (2020-2025)
5.2 Global Solid Tumor Non-Conventional Testing Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Solid Tumor Non-Conventional Testing Market Size (2020-2031)
6.2 North America Solid Tumor Non-Conventional Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Solid Tumor Non-Conventional Testing Market Size by Country (2020-2025)
6.4 North America Solid Tumor Non-Conventional Testing Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Solid Tumor Non-Conventional Testing Market Size (2020-2031)
7.2 Europe Solid Tumor Non-Conventional Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Solid Tumor Non-Conventional Testing Market Size by Country (2020-2025)
7.4 Europe Solid Tumor Non-Conventional Testing Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Solid Tumor Non-Conventional Testing Market Size (2020-2031)
8.2 Asia-Pacific Solid Tumor Non-Conventional Testing Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Solid Tumor Non-Conventional Testing Market Size by Region (2020-2025)
8.4 Asia-Pacific Solid Tumor Non-Conventional Testing Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Solid Tumor Non-Conventional Testing Market Size (2020-2031)
9.2 Latin America Solid Tumor Non-Conventional Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Solid Tumor Non-Conventional Testing Market Size by Country (2020-2025)
9.4 Latin America Solid Tumor Non-Conventional Testing Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Solid Tumor Non-Conventional Testing Market Size (2020-2031)
10.2 Middle East & Africa Solid Tumor Non-Conventional Testing Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Solid Tumor Non-Conventional Testing Market Size by Country (2020-2025)
10.4 Middle East & Africa Solid Tumor Non-Conventional Testing Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Details
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Solid Tumor Non-Conventional Testing Introduction
11.1.4 Abbott Laboratories Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.1.5 Abbott Laboratories Recent Development
11.2 Agilent Technologies
11.2.1 Agilent Technologies Company Details
11.2.2 Agilent Technologies Business Overview
11.2.3 Agilent Technologies Solid Tumor Non-Conventional Testing Introduction
11.2.4 Agilent Technologies Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.2.5 Agilent Technologies Recent Development
11.3 Avant Diagnostics, Inc.
11.3.1 Avant Diagnostics, Inc. Company Details
11.3.2 Avant Diagnostics, Inc. Business Overview
11.3.3 Avant Diagnostics, Inc. Solid Tumor Non-Conventional Testing Introduction
11.3.4 Avant Diagnostics, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.3.5 Avant Diagnostics, Inc. Recent Development
11.4 Advanced Cell Diagnostics, Inc.
11.4.1 Advanced Cell Diagnostics, Inc. Company Details
11.4.2 Advanced Cell Diagnostics, Inc. Business Overview
11.4.3 Advanced Cell Diagnostics, Inc. Solid Tumor Non-Conventional Testing Introduction
11.4.4 Advanced Cell Diagnostics, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.4.5 Advanced Cell Diagnostics, Inc. Recent Development
11.5 Agena Bioscience, Inc.
11.5.1 Agena Bioscience, Inc. Company Details
11.5.2 Agena Bioscience, Inc. Business Overview
11.5.3 Agena Bioscience, Inc. Solid Tumor Non-Conventional Testing Introduction
11.5.4 Agena Bioscience, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.5.5 Agena Bioscience, Inc. Recent Development
11.6 ARUP Laboratories
11.6.1 ARUP Laboratories Company Details
11.6.2 ARUP Laboratories Business Overview
11.6.3 ARUP Laboratories Solid Tumor Non-Conventional Testing Introduction
11.6.4 ARUP Laboratories Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.6.5 ARUP Laboratories Recent Development
11.7 Bio-Rad Laboratories, Inc.
11.7.1 Bio-Rad Laboratories, Inc. Company Details
11.7.2 Bio-Rad Laboratories, Inc. Business Overview
11.7.3 Bio-Rad Laboratories, Inc. Solid Tumor Non-Conventional Testing Introduction
11.7.4 Bio-Rad Laboratories, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.7.5 Bio-Rad Laboratories, Inc. Recent Development
11.8 Biocare Medical, LLC.
11.8.1 Biocare Medical, LLC. Company Details
11.8.2 Biocare Medical, LLC. Business Overview
11.8.3 Biocare Medical, LLC. Solid Tumor Non-Conventional Testing Introduction
11.8.4 Biocare Medical, LLC. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.8.5 Biocare Medical, LLC. Recent Development
11.9 Caris Life Sciences.
11.9.1 Caris Life Sciences. Company Details
11.9.2 Caris Life Sciences. Business Overview
11.9.3 Caris Life Sciences. Solid Tumor Non-Conventional Testing Introduction
11.9.4 Caris Life Sciences. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.9.5 Caris Life Sciences. Recent Development
11.10 F. Hoffmann-La Roche Ltd
11.10.1 F. Hoffmann-La Roche Ltd Company Details
11.10.2 F. Hoffmann-La Roche Ltd Business Overview
11.10.3 F. Hoffmann-La Roche Ltd Solid Tumor Non-Conventional Testing Introduction
11.10.4 F. Hoffmann-La Roche Ltd Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.10.5 F. Hoffmann-La Roche Ltd Recent Development
11.11 Foundation Medicine
11.11.1 Foundation Medicine Company Details
11.11.2 Foundation Medicine Business Overview
11.11.3 Foundation Medicine Solid Tumor Non-Conventional Testing Introduction
11.11.4 Foundation Medicine Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.11.5 Foundation Medicine Recent Development
11.12 Genomic Testing Cooperative
11.12.1 Genomic Testing Cooperative Company Details
11.12.2 Genomic Testing Cooperative Business Overview
11.12.3 Genomic Testing Cooperative Solid Tumor Non-Conventional Testing Introduction
11.12.4 Genomic Testing Cooperative Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.12.5 Genomic Testing Cooperative Recent Development
11.13 Guardant Health
11.13.1 Guardant Health Company Details
11.13.2 Guardant Health Business Overview
11.13.3 Guardant Health Solid Tumor Non-Conventional Testing Introduction
11.13.4 Guardant Health Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.13.5 Guardant Health Recent Development
11.14 HTG Molecular Diagnostics, Inc.
11.14.1 HTG Molecular Diagnostics, Inc. Company Details
11.14.2 HTG Molecular Diagnostics, Inc. Business Overview
11.14.3 HTG Molecular Diagnostics, Inc. Solid Tumor Non-Conventional Testing Introduction
11.14.4 HTG Molecular Diagnostics, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.14.5 HTG Molecular Diagnostics, Inc. Recent Development
11.15 Illumina, Inc.
11.15.1 Illumina, Inc. Company Details
11.15.2 Illumina, Inc. Business Overview
11.15.3 Illumina, Inc. Solid Tumor Non-Conventional Testing Introduction
11.15.4 Illumina, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.15.5 Illumina, Inc. Recent Development
11.16 Invitae Corporation
11.16.1 Invitae Corporation Company Details
11.16.2 Invitae Corporation Business Overview
11.16.3 Invitae Corporation Solid Tumor Non-Conventional Testing Introduction
11.16.4 Invitae Corporation Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.16.5 Invitae Corporation Recent Development
11.17 Invivoscribe, Inc.
11.17.1 Invivoscribe, Inc. Company Details
11.17.2 Invivoscribe, Inc. Business Overview
11.17.3 Invivoscribe, Inc. Solid Tumor Non-Conventional Testing Introduction
11.17.4 Invivoscribe, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.17.5 Invivoscribe, Inc. Recent Development
11.18 Johnson & Johnson
11.18.1 Johnson & Johnson Company Details
11.18.2 Johnson & Johnson Business Overview
11.18.3 Johnson & Johnson Solid Tumor Non-Conventional Testing Introduction
11.18.4 Johnson & Johnson Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.18.5 Johnson & Johnson Recent Development
11.19 Laboratory Corporation of America Holdings
11.19.1 Laboratory Corporation of America Holdings Company Details
11.19.2 Laboratory Corporation of America Holdings Business Overview
11.19.3 Laboratory Corporation of America Holdings Solid Tumor Non-Conventional Testing Introduction
11.19.4 Laboratory Corporation of America Holdings Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.19.5 Laboratory Corporation of America Holdings Recent Development
11.20 MedGenome Labs Private Ltd.
11.20.1 MedGenome Labs Private Ltd. Company Details
11.20.2 MedGenome Labs Private Ltd. Business Overview
11.20.3 MedGenome Labs Private Ltd. Solid Tumor Non-Conventional Testing Introduction
11.20.4 MedGenome Labs Private Ltd. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.20.5 MedGenome Labs Private Ltd. Recent Development
11.21 Myraid Genetics, Inc.
11.21.1 Myraid Genetics, Inc. Company Details
11.21.2 Myraid Genetics, Inc. Business Overview
11.21.3 Myraid Genetics, Inc. Solid Tumor Non-Conventional Testing Introduction
11.21.4 Myraid Genetics, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.21.5 Myraid Genetics, Inc. Recent Development
11.22 Nanjing Geneseeq
11.22.1 Nanjing Geneseeq Company Details
11.22.2 Nanjing Geneseeq Business Overview
11.22.3 Nanjing Geneseeq Solid Tumor Non-Conventional Testing Introduction
11.22.4 Nanjing Geneseeq Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.22.5 Nanjing Geneseeq Recent Development
11.23 NanoString
11.23.1 NanoString Company Details
11.23.2 NanoString Business Overview
11.23.3 NanoString Solid Tumor Non-Conventional Testing Introduction
11.23.4 NanoString Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.23.5 NanoString Recent Development
11.24 NeoGenomics Laboratories
11.24.1 NeoGenomics Laboratories Company Details
11.24.2 NeoGenomics Laboratories Business Overview
11.24.3 NeoGenomics Laboratories Solid Tumor Non-Conventional Testing Introduction
11.24.4 NeoGenomics Laboratories Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.24.5 NeoGenomics Laboratories Recent Development
11.25 Opko Health, Inc.
11.25.1 Opko Health, Inc. Company Details
11.25.2 Opko Health, Inc. Business Overview
11.25.3 Opko Health, Inc. Solid Tumor Non-Conventional Testing Introduction
11.25.4 Opko Health, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.25.5 Opko Health, Inc. Recent Development
11.26 QIAGEN
11.26.1 QIAGEN Company Details
11.26.2 QIAGEN Business Overview
11.26.3 QIAGEN Solid Tumor Non-Conventional Testing Introduction
11.26.4 QIAGEN Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.26.5 QIAGEN Recent Development
11.27 Quest Diagnostics Incorporated.
11.27.1 Quest Diagnostics Incorporated. Company Details
11.27.2 Quest Diagnostics Incorporated. Business Overview
11.27.3 Quest Diagnostics Incorporated. Solid Tumor Non-Conventional Testing Introduction
11.27.4 Quest Diagnostics Incorporated. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.27.5 Quest Diagnostics Incorporated. Recent Development
11.28 Thermo Fisher Scientific, Inc.
11.28.1 Thermo Fisher Scientific, Inc. Company Details
11.28.2 Thermo Fisher Scientific, Inc. Business Overview
11.28.3 Thermo Fisher Scientific, Inc. Solid Tumor Non-Conventional Testing Introduction
11.28.4 Thermo Fisher Scientific, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.28.5 Thermo Fisher Scientific, Inc. Recent Development
11.29 VYANTbio.
11.29.1 VYANTbio. Company Details
11.29.2 VYANTbio. Business Overview
11.29.3 VYANTbio. Solid Tumor Non-Conventional Testing Introduction
11.29.4 VYANTbio. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025)
11.29.5 VYANTbio. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Solid Tumor Non-Conventional Testing Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Fluorescence in-situ Hybridization (FISH)
Table 3. Key Players of Immunohistochemistry (IHC)
Table 4. Key Players of Polymerase Chain Reaction (PCR)
Table 5. Key Players of Next-generation Sequencing (NGS)
Table 6. Key Players of Others
Table 7. Global Solid Tumor Non-Conventional Testing Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Solid Tumor Non-Conventional Testing Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 9. Global Solid Tumor Non-Conventional Testing Market Size by Region (2020-2025) & (US$ Million)
Table 10. Global Solid Tumor Non-Conventional Testing Market Share by Region (2020-2025)
Table 11. Global Solid Tumor Non-Conventional Testing Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 12. Global Solid Tumor Non-Conventional Testing Market Share by Region (2026-2031)
Table 13. Solid Tumor Non-Conventional Testing Market Trends
Table 14. Solid Tumor Non-Conventional Testing Market Drivers
Table 15. Solid Tumor Non-Conventional Testing Market Challenges
Table 16. Solid Tumor Non-Conventional Testing Market Restraints
Table 17. Global Solid Tumor Non-Conventional Testing Revenue by Players (2020-2025) & (US$ Million)
Table 18. Global Solid Tumor Non-Conventional Testing Market Share by Players (2020-2025)
Table 19. Global Top Solid Tumor Non-Conventional Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Solid Tumor Non-Conventional Testing as of 2024)
Table 20. Ranking of Global Top Solid Tumor Non-Conventional Testing Companies by Revenue (US$ Million) in 2024
Table 21. Global 5 Largest Players Market Share by Solid Tumor Non-Conventional Testing Revenue (CR5 and HHI) & (2020-2025)
Table 22. Global Key Players of Solid Tumor Non-Conventional Testing, Headquarters and Area Served
Table 23. Global Key Players of Solid Tumor Non-Conventional Testing, Product and Application
Table 24. Global Key Players of Solid Tumor Non-Conventional Testing, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Solid Tumor Non-Conventional Testing Market Size by Type (2020-2025) & (US$ Million)
Table 27. Global Solid Tumor Non-Conventional Testing Revenue Market Share by Type (2020-2025)
Table 28. Global Solid Tumor Non-Conventional Testing Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 29. Global Solid Tumor Non-Conventional Testing Revenue Market Share by Type (2026-2031)
Table 30. Global Solid Tumor Non-Conventional Testing Market Size by Application (2020-2025) & (US$ Million)
Table 31. Global Solid Tumor Non-Conventional Testing Revenue Market Share by Application (2020-2025)
Table 32. Global Solid Tumor Non-Conventional Testing Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 33. Global Solid Tumor Non-Conventional Testing Revenue Market Share by Application (2026-2031)
Table 34. North America Solid Tumor Non-Conventional Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 35. North America Solid Tumor Non-Conventional Testing Market Size by Country (2020-2025) & (US$ Million)
Table 36. North America Solid Tumor Non-Conventional Testing Market Size by Country (2026-2031) & (US$ Million)
Table 37. Europe Solid Tumor Non-Conventional Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 38. Europe Solid Tumor Non-Conventional Testing Market Size by Country (2020-2025) & (US$ Million)
Table 39. Europe Solid Tumor Non-Conventional Testing Market Size by Country (2026-2031) & (US$ Million)
Table 40. Asia-Pacific Solid Tumor Non-Conventional Testing Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 41. Asia-Pacific Solid Tumor Non-Conventional Testing Market Size by Region (2020-2025) & (US$ Million)
Table 42. Asia-Pacific Solid Tumor Non-Conventional Testing Market Size by Region (2026-2031) & (US$ Million)
Table 43. Latin America Solid Tumor Non-Conventional Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 44. Latin America Solid Tumor Non-Conventional Testing Market Size by Country (2020-2025) & (US$ Million)
Table 45. Latin America Solid Tumor Non-Conventional Testing Market Size by Country (2026-2031) & (US$ Million)
Table 46. Middle East & Africa Solid Tumor Non-Conventional Testing Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 47. Middle East & Africa Solid Tumor Non-Conventional Testing Market Size by Country (2020-2025) & (US$ Million)
Table 48. Middle East & Africa Solid Tumor Non-Conventional Testing Market Size by Country (2026-2031) & (US$ Million)
Table 49. Abbott Laboratories Company Details
Table 50. Abbott Laboratories Business Overview
Table 51. Abbott Laboratories Solid Tumor Non-Conventional Testing Product
Table 52. Abbott Laboratories Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 53. Abbott Laboratories Recent Development
Table 54. Agilent Technologies Company Details
Table 55. Agilent Technologies Business Overview
Table 56. Agilent Technologies Solid Tumor Non-Conventional Testing Product
Table 57. Agilent Technologies Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 58. Agilent Technologies Recent Development
Table 59. Avant Diagnostics, Inc. Company Details
Table 60. Avant Diagnostics, Inc. Business Overview
Table 61. Avant Diagnostics, Inc. Solid Tumor Non-Conventional Testing Product
Table 62. Avant Diagnostics, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 63. Avant Diagnostics, Inc. Recent Development
Table 64. Advanced Cell Diagnostics, Inc. Company Details
Table 65. Advanced Cell Diagnostics, Inc. Business Overview
Table 66. Advanced Cell Diagnostics, Inc. Solid Tumor Non-Conventional Testing Product
Table 67. Advanced Cell Diagnostics, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 68. Advanced Cell Diagnostics, Inc. Recent Development
Table 69. Agena Bioscience, Inc. Company Details
Table 70. Agena Bioscience, Inc. Business Overview
Table 71. Agena Bioscience, Inc. Solid Tumor Non-Conventional Testing Product
Table 72. Agena Bioscience, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 73. Agena Bioscience, Inc. Recent Development
Table 74. ARUP Laboratories Company Details
Table 75. ARUP Laboratories Business Overview
Table 76. ARUP Laboratories Solid Tumor Non-Conventional Testing Product
Table 77. ARUP Laboratories Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 78. ARUP Laboratories Recent Development
Table 79. Bio-Rad Laboratories, Inc. Company Details
Table 80. Bio-Rad Laboratories, Inc. Business Overview
Table 81. Bio-Rad Laboratories, Inc. Solid Tumor Non-Conventional Testing Product
Table 82. Bio-Rad Laboratories, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 83. Bio-Rad Laboratories, Inc. Recent Development
Table 84. Biocare Medical, LLC. Company Details
Table 85. Biocare Medical, LLC. Business Overview
Table 86. Biocare Medical, LLC. Solid Tumor Non-Conventional Testing Product
Table 87. Biocare Medical, LLC. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 88. Biocare Medical, LLC. Recent Development
Table 89. Caris Life Sciences. Company Details
Table 90. Caris Life Sciences. Business Overview
Table 91. Caris Life Sciences. Solid Tumor Non-Conventional Testing Product
Table 92. Caris Life Sciences. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 93. Caris Life Sciences. Recent Development
Table 94. F. Hoffmann-La Roche Ltd Company Details
Table 95. F. Hoffmann-La Roche Ltd Business Overview
Table 96. F. Hoffmann-La Roche Ltd Solid Tumor Non-Conventional Testing Product
Table 97. F. Hoffmann-La Roche Ltd Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 98. F. Hoffmann-La Roche Ltd Recent Development
Table 99. Foundation Medicine Company Details
Table 100. Foundation Medicine Business Overview
Table 101. Foundation Medicine Solid Tumor Non-Conventional Testing Product
Table 102. Foundation Medicine Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 103. Foundation Medicine Recent Development
Table 104. Genomic Testing Cooperative Company Details
Table 105. Genomic Testing Cooperative Business Overview
Table 106. Genomic Testing Cooperative Solid Tumor Non-Conventional Testing Product
Table 107. Genomic Testing Cooperative Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 108. Genomic Testing Cooperative Recent Development
Table 109. Guardant Health Company Details
Table 110. Guardant Health Business Overview
Table 111. Guardant Health Solid Tumor Non-Conventional Testing Product
Table 112. Guardant Health Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 113. Guardant Health Recent Development
Table 114. HTG Molecular Diagnostics, Inc. Company Details
Table 115. HTG Molecular Diagnostics, Inc. Business Overview
Table 116. HTG Molecular Diagnostics, Inc. Solid Tumor Non-Conventional Testing Product
Table 117. HTG Molecular Diagnostics, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 118. HTG Molecular Diagnostics, Inc. Recent Development
Table 119. Illumina, Inc. Company Details
Table 120. Illumina, Inc. Business Overview
Table 121. Illumina, Inc. Solid Tumor Non-Conventional Testing Product
Table 122. Illumina, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 123. Illumina, Inc. Recent Development
Table 124. Invitae Corporation Company Details
Table 125. Invitae Corporation Business Overview
Table 126. Invitae Corporation Solid Tumor Non-Conventional Testing Product
Table 127. Invitae Corporation Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 128. Invitae Corporation Recent Development
Table 129. Invivoscribe, Inc. Company Details
Table 130. Invivoscribe, Inc. Business Overview
Table 131. Invivoscribe, Inc. Solid Tumor Non-Conventional Testing Product
Table 132. Invivoscribe, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 133. Invivoscribe, Inc. Recent Development
Table 134. Johnson & Johnson Company Details
Table 135. Johnson & Johnson Business Overview
Table 136. Johnson & Johnson Solid Tumor Non-Conventional Testing Product
Table 137. Johnson & Johnson Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 138. Johnson & Johnson Recent Development
Table 139. Laboratory Corporation of America Holdings Company Details
Table 140. Laboratory Corporation of America Holdings Business Overview
Table 141. Laboratory Corporation of America Holdings Solid Tumor Non-Conventional Testing Product
Table 142. Laboratory Corporation of America Holdings Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 143. Laboratory Corporation of America Holdings Recent Development
Table 144. MedGenome Labs Private Ltd. Company Details
Table 145. MedGenome Labs Private Ltd. Business Overview
Table 146. MedGenome Labs Private Ltd. Solid Tumor Non-Conventional Testing Product
Table 147. MedGenome Labs Private Ltd. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 148. MedGenome Labs Private Ltd. Recent Development
Table 149. Myraid Genetics, Inc. Company Details
Table 150. Myraid Genetics, Inc. Business Overview
Table 151. Myraid Genetics, Inc. Solid Tumor Non-Conventional Testing Product
Table 152. Myraid Genetics, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 153. Myraid Genetics, Inc. Recent Development
Table 154. Nanjing Geneseeq Company Details
Table 155. Nanjing Geneseeq Business Overview
Table 156. Nanjing Geneseeq Solid Tumor Non-Conventional Testing Product
Table 157. Nanjing Geneseeq Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 158. Nanjing Geneseeq Recent Development
Table 159. NanoString Company Details
Table 160. NanoString Business Overview
Table 161. NanoString Solid Tumor Non-Conventional Testing Product
Table 162. NanoString Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 163. NanoString Recent Development
Table 164. NeoGenomics Laboratories Company Details
Table 165. NeoGenomics Laboratories Business Overview
Table 166. NeoGenomics Laboratories Solid Tumor Non-Conventional Testing Product
Table 167. NeoGenomics Laboratories Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 168. NeoGenomics Laboratories Recent Development
Table 169. Opko Health, Inc. Company Details
Table 170. Opko Health, Inc. Business Overview
Table 171. Opko Health, Inc. Solid Tumor Non-Conventional Testing Product
Table 172. Opko Health, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 173. Opko Health, Inc. Recent Development
Table 174. QIAGEN Company Details
Table 175. QIAGEN Business Overview
Table 176. QIAGEN Solid Tumor Non-Conventional Testing Product
Table 177. QIAGEN Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 178. QIAGEN Recent Development
Table 179. Quest Diagnostics Incorporated. Company Details
Table 180. Quest Diagnostics Incorporated. Business Overview
Table 181. Quest Diagnostics Incorporated. Solid Tumor Non-Conventional Testing Product
Table 182. Quest Diagnostics Incorporated. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 183. Quest Diagnostics Incorporated. Recent Development
Table 184. Thermo Fisher Scientific, Inc. Company Details
Table 185. Thermo Fisher Scientific, Inc. Business Overview
Table 186. Thermo Fisher Scientific, Inc. Solid Tumor Non-Conventional Testing Product
Table 187. Thermo Fisher Scientific, Inc. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 188. Thermo Fisher Scientific, Inc. Recent Development
Table 189. VYANTbio. Company Details
Table 190. VYANTbio. Business Overview
Table 191. VYANTbio. Solid Tumor Non-Conventional Testing Product
Table 192. VYANTbio. Revenue in Solid Tumor Non-Conventional Testing Business (2020-2025) & (US$ Million)
Table 193. VYANTbio. Recent Development
Table 194. Research Programs/Design for This Report
Table 195. Key Data Information from Secondary Sources
Table 196. Key Data Information from Primary Sources
Table 197. Authors List of This Report


List of Figures
Figure 1. Solid Tumor Non-Conventional Testing Picture
Figure 2. Global Solid Tumor Non-Conventional Testing Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Solid Tumor Non-Conventional Testing Market Share by Type: 2024 VS 2031
Figure 4. Fluorescence in-situ Hybridization (FISH) Features
Figure 5. Immunohistochemistry (IHC) Features
Figure 6. Polymerase Chain Reaction (PCR) Features
Figure 7. Next-generation Sequencing (NGS) Features
Figure 8. Others Features
Figure 9. Global Solid Tumor Non-Conventional Testing Market Size by Application (2020-2031) & (US$ Million)
Figure 10. Global Solid Tumor Non-Conventional Testing Market Share by Application: 2024 VS 2031
Figure 11. Hospitals Case Studies
Figure 12. Pharmaceutical and Biotechnology Companies Case Studies
Figure 13. Others Case Studies
Figure 14. Solid Tumor Non-Conventional Testing Report Years Considered
Figure 15. Global Solid Tumor Non-Conventional Testing Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 16. Global Solid Tumor Non-Conventional Testing Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 17. Global Solid Tumor Non-Conventional Testing Market Share by Region: 2024 VS 2031
Figure 18. Global Solid Tumor Non-Conventional Testing Market Share by Players in 2024
Figure 19. Global Top Solid Tumor Non-Conventional Testing Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Solid Tumor Non-Conventional Testing as of 2024)
Figure 20. The Top 10 and 5 Players Market Share by Solid Tumor Non-Conventional Testing Revenue in 2024
Figure 21. North America Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. North America Solid Tumor Non-Conventional Testing Market Share by Country (2020-2031)
Figure 23. United States Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Canada Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Europe Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Solid Tumor Non-Conventional Testing Market Share by Country (2020-2031)
Figure 27. Germany Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. France Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. U.K. Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Italy Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Russia Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Nordic Countries Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Asia-Pacific Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Solid Tumor Non-Conventional Testing Market Share by Region (2020-2031)
Figure 35. China Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Japan Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. South Korea Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Southeast Asia Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. India Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Australia Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Latin America Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Solid Tumor Non-Conventional Testing Market Share by Country (2020-2031)
Figure 43. Mexico Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Brazil Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Middle East & Africa Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Solid Tumor Non-Conventional Testing Market Share by Country (2020-2031)
Figure 47. Turkey Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Saudi Arabia Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. UAE Solid Tumor Non-Conventional Testing Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. Abbott Laboratories Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 51. Agilent Technologies Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 52. Avant Diagnostics, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 53. Advanced Cell Diagnostics, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 54. Agena Bioscience, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 55. ARUP Laboratories Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 56. Bio-Rad Laboratories, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 57. Biocare Medical, LLC. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 58. Caris Life Sciences. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 59. F. Hoffmann-La Roche Ltd Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 60. Foundation Medicine Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 61. Genomic Testing Cooperative Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 62. Guardant Health Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 63. HTG Molecular Diagnostics, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 64. Illumina, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 65. Invitae Corporation Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 66. Invivoscribe, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 67. Johnson & Johnson Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 68. Laboratory Corporation of America Holdings Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 69. MedGenome Labs Private Ltd. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 70. Myraid Genetics, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 71. Nanjing Geneseeq Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 72. NanoString Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 73. NeoGenomics Laboratories Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 74. Opko Health, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 75. QIAGEN Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 76. Quest Diagnostics Incorporated. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 77. Thermo Fisher Scientific, Inc. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 78. VYANTbio. Revenue Growth Rate in Solid Tumor Non-Conventional Testing Business (2020-2025)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed

Your Name

Your E-mail

Your message

Submit